Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 53.38
EXAS's Cash to Debt is ranked higher than
67% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. EXAS: 53.38 )
Ranked among companies with meaningful Cash to Debt only.
EXAS' s Cash to Debt Range Over the Past 10 Years
Min: 12.24  Med: 10000.00 Max: No Debt
Current: 53.38
Equity to Asset 0.89
EXAS's Equity to Asset is ranked higher than
92% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EXAS: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
EXAS' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.70 Max: 0.96
Current: 0.89
-0.41
0.96
F-Score: 4
Z-Score: 17.33
M-Score: 3.13
WACC vs ROIC
4.63%
-781.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -341.84
EXAS's Operating margin (%) is ranked lower than
84% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. EXAS: -341.84 )
Ranked among companies with meaningful Operating margin (%) only.
EXAS' s Operating margin (%) Range Over the Past 10 Years
Min: -5591.71  Med: -420.54 Max: 1150.29
Current: -341.84
-5591.71
1150.29
Net-margin (%) -338.91
EXAS's Net-margin (%) is ranked lower than
85% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. EXAS: -338.91 )
Ranked among companies with meaningful Net-margin (%) only.
EXAS' s Net-margin (%) Range Over the Past 10 Years
Min: -5564.4  Med: -403.80 Max: 1123.53
Current: -338.91
-5564.4
1123.53
ROE (%) -58.06
EXAS's ROE (%) is ranked lower than
74% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. EXAS: -58.06 )
Ranked among companies with meaningful ROE (%) only.
EXAS' s ROE (%) Range Over the Past 10 Years
Min: -505.37  Med: -54.42 Max: -26.92
Current: -58.06
-505.37
-26.92
ROA (%) -52.50
EXAS's ROA (%) is ranked lower than
74% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. EXAS: -52.50 )
Ranked among companies with meaningful ROA (%) only.
EXAS' s ROA (%) Range Over the Past 10 Years
Min: -95.07  Med: -45.08 Max: -18.9
Current: -52.5
-95.07
-18.9
ROC (Joel Greenblatt) (%) -563.65
EXAS's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. EXAS: -563.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXAS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3463.3  Med: -1723.17 Max: -583.97
Current: -563.65
-3463.3
-583.97
Revenue Growth (3Y)(%) 82.90
EXAS's Revenue Growth (3Y)(%) is ranked higher than
98% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.10 vs. EXAS: 82.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXAS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.60 Max: 302.1
Current: 82.9
0
302.1
EBITDA Growth (3Y)(%) 23.50
EXAS's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. EXAS: 23.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXAS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.4  Med: -13.00 Max: 46.1
Current: 23.5
-39.4
46.1
EPS Growth (3Y)(%) 24.80
EXAS's EPS Growth (3Y)(%) is ranked higher than
80% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. EXAS: 24.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXAS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.1  Med: -15.30 Max: 46.9
Current: 24.8
-43.1
46.9
» EXAS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EXAS Guru Trades in Q2 2015

PRIMECAP Management 2,631,300 sh (+4.16%)
Steven Cohen 74,400 sh (-53.18%)
» More
Q3 2015

EXAS Guru Trades in Q3 2015

PRIMECAP Management 2,736,300 sh (+3.99%)
Steven Cohen 12,000 sh (-83.87%)
» More
Q4 2015

EXAS Guru Trades in Q4 2015

Jim Simons 12,160 sh (New)
Steven Cohen 2,468,828 sh (+20473.57%)
PRIMECAP Management 3,096,300 sh (+13.16%)
» More
Q1 2016

EXAS Guru Trades in Q1 2016

Paul Tudor Jones 19,436 sh (New)
Jim Simons 210,100 sh (+1627.80%)
PRIMECAP Management 4,516,300 sh (+45.86%)
Steven Cohen 747,500 sh (-69.72%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:KANG, NAS:AFFX, NAS:AXDX, NAS:ABAX, NAS:ALOG, NAS:GHDX, NAS:VIVO, NAS:FMI, NAS:NEO, NAS:NTRA, NAS:QDEL, NYSE:ARA, OTCPK:EPLYF, NAS:NVDQ, NAS:BEAT, NAS:NRCIB, AMEX:ONVO, NAS:NEOG, AMEX:SENS, NAS:SRDX » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. It has developed a non‑invasive, patient friendly screening test called Cologuard(R).

Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. It is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.

Ratios

vs
industry
vs
history
P/B 4.22
EXAS's P/B is ranked lower than
63% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. EXAS: 4.22 )
Ranked among companies with meaningful P/B only.
EXAS' s P/B Range Over the Past 10 Years
Min: 1.5  Med: 6.49 Max: 36.44
Current: 4.22
1.5
36.44
P/S 23.28
EXAS's P/S is ranked lower than
85% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. EXAS: 23.28 )
Ranked among companies with meaningful P/S only.
EXAS' s P/S Range Over the Past 10 Years
Min: 9.28  Med: 45.92 Max: 1306.32
Current: 23.28
9.28
1306.32
Current Ratio 11.51
EXAS's Current Ratio is ranked higher than
94% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. EXAS: 11.51 )
Ranked among companies with meaningful Current Ratio only.
EXAS' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.57 Max: 50.84
Current: 11.51
1.02
50.84
Quick Ratio 11.18
EXAS's Quick Ratio is ranked higher than
94% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. EXAS: 11.18 )
Ranked among companies with meaningful Quick Ratio only.
EXAS' s Quick Ratio Range Over the Past 10 Years
Min: 1.02  Med: 8.57 Max: 50.84
Current: 11.18
1.02
50.84
Days Inventory 81.00
EXAS's Days Inventory is ranked higher than
54% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.32 vs. EXAS: 81.00 )
Ranked among companies with meaningful Days Inventory only.
EXAS' s Days Inventory Range Over the Past 10 Years
Min: 79.66  Med: 124.58 Max: 169.5
Current: 81
79.66
169.5
Days Sales Outstanding 41.03
EXAS's Days Sales Outstanding is ranked higher than
80% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. EXAS: 41.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXAS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.66  Med: 162.50 Max: 279.33
Current: 41.03
45.66
279.33
Days Payable 35.33
EXAS's Days Payable is ranked lower than
63% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. EXAS: 35.33 )
Ranked among companies with meaningful Days Payable only.
EXAS' s Days Payable Range Over the Past 10 Years
Min: 49.28  Med: 1526.07 Max: 249295
Current: 35.33
49.28
249295

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.39
EXAS's Price/Net Cash is ranked higher than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.51 vs. EXAS: 5.39 )
Ranked among companies with meaningful Price/Net Cash only.
EXAS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.02  Med: 6.63 Max: 90
Current: 5.39
2.02
90
Price/Net Current Asset Value 4.91
EXAS's Price/Net Current Asset Value is ranked higher than
62% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.06 vs. EXAS: 4.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EXAS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.98  Med: 6.54 Max: 60
Current: 4.91
1.98
60
Price/Tangible Book 4.23
EXAS's Price/Tangible Book is ranked higher than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. EXAS: 4.23 )
Ranked among companies with meaningful Price/Tangible Book only.
EXAS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.87  Med: 6.18 Max: 33.71
Current: 4.23
1.87
33.71
Price/Median PS Value 0.50
EXAS's Price/Median PS Value is ranked higher than
84% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. EXAS: 0.50 )
Ranked among companies with meaningful Price/Median PS Value only.
EXAS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.24  Med: 1.50 Max: 187.2
Current: 0.5
0.24
187.2
Earnings Yield (Greenblatt) (%) -17.65
EXAS's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. EXAS: -17.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXAS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -106.22  Med: 0.00 Max: 41.6
Current: -17.65
-106.22
41.6

More Statistics

Revenue (TTM) (Mil) $50.01
EPS (TTM) $ -1.80
Beta0.41
Short Percentage of Float32.95%
52-Week Range $4.67 - 25.90
Shares Outstanding (Mil)97.79

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 90 163 255
EPS ($) -2.02 -1.70 -1.14
EPS w/o NRI ($) -2.02 -1.70 -1.14
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Whitney Tilson's Robin Hood Conference Presentation Nov 19 2015 
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 

More From Other Websites
What's in Store for these 5 Drug Stocks in Q2 Earnings? Jul 25 2016
NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures Jul 13 2016
NCQA Proposes Inclusion of Cologuard in 2017 HEDIS Quality Measures Jul 13 2016
Exact Sciences drawing short-term bulls Jul 13 2016
Exact Sciences (EXAS) Stock Rising on Illumina Takeover Speculation Jul 12 2016
5 Hot Stocks to Watch Right Now Jun 30 2016
4 health stocks to watch Jun 30 2016
Exact Sciences to host second-quarter 2016 results, annual meeting webcasts and calls Jun 29 2016
Biotech Stock Bounce Picks Up Momentum Jun 23 2016
Exact Sciences: What If Its Price Target is Raised and No One Notices? Jun 21 2016
ETF’s with exposure to EXACT Sciences Corp. : June 20, 2016 Jun 20 2016
Featured Research Report on Medical Laboratories and Research Stocks Jun 17 2016
5 stocks to watch Jun 16 2016
Exact Sciences shares surge on leak of test recommendations Jun 16 2016
Why Are These Five Stocks on the Move Today? Jun 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)